NEW YORK, October 30, 2018 – Levi & Korsinsky announces a class action on behalf of all persons or entities who purchased or otherwise acquired securities of AbbVie Inc. (“AbbVie”) (NYSE: ABBV) between October 25, 2013 and September 18, 2018. You are hereby notified that the ABBV class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information about the AbbVie class action go to: https://www.zlk.com/pslra-1/abbvie-inc-loss-form? or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would lead to heightened scrutiny by State governments and agencies; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

If you suffered a loss in AbbVie you have until November 20, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com